Maravai LifeSciences Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
44.4%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$211.6Mnext fiscal year
FY EPS (est.)
-$0.18next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly65.8MTarget: Full-year 2026 guidance of $205.0M to $215.0M
Adjusted EBITDA Quarterly20.3M
Free Cash Flow Quarterly4.2MTarget: Maintain positive free cash flow throughout 2026
Watch Items
- Non-COVID mRNA clinical pipeline progressionTrigger: Customer clinical trial advancements or regulatory approvals using CleanCap technologyAction: Monitor customer pipeline updates and contract announcements
- Post-restructuring cost control and operating leverageTrigger: Operating margins falling below target levels or cost creep post-$65M reduction programAction: Review quarterly SG&A and R&D expense lines relative to revenue growth
Research as of 20 Jun 2026